$12.17
10.05% today
NYSE, Apr 04, 08:51 pm CET
ISIN
US6031701013
Symbol
MLYS
Sector
Industry

Mineralys Therapeutics Stock price

$13.53
+4.59 51.34% 1M
+0.62 4.80% 6M
+1.22 9.91% YTD
+0.63 4.88% 1Y
-4.91 26.63% 3Y
-4.91 26.63% 5Y
-4.91 26.63% 10Y
NYSE, Closing price Thu, Apr 03 2025
-0.47 3.36%
ISIN
US6031701013
Symbol
MLYS
Sector
Industry

Key metrics

Market capitalization $849.48m
Enterprise Value $651.29m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 3.52
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-192.40m
Free Cash Flow (TTM) Free Cash Flow $-166.41m
Cash position $198.19m
EPS (TTM) EPS $-3.64
P/E forward negative
Short interest 4.71%
Show more

Is Mineralys Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Mineralys Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Mineralys Therapeutics forecast:

8x Buy
100%

Analyst Opinions

8 Analysts have issued a Mineralys Therapeutics forecast:

Buy
100%

Financial data from Mineralys Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.04 0.04
-
-
-0.04 -0.04
-
-
- Selling and Administrative Expenses 24 24
66% 66%
-
- Research and Development Expense 169 169
140% 140%
-
-192 -192
127% 127%
-
- Depreciation and Amortization 0.04 0.04
-
-
EBIT (Operating Income) EBIT -192 -192
127% 127%
-
Net Profit -178 -178
147% 147%
-

In millions USD.

Don't miss a Thing! We will send you all news about Mineralys Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Mineralys Therapeutics Stock News

Neutral
GlobeNewsWire
6 days ago
– Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and 7.9 mmHg placebo-adjusted reduction (p=0.001), assessed by 24hr ABPM at week 12, with favorable safety and tolerability profile –
Neutral
24/7 Wall Street
9 days ago
After a rough patch, it seems the biotech industry may be staging a comeback. Several biotech firms have gone public this year, and those focused on obesity treatments, gene therapies, and more have high expectations.
Neutral
GlobeNewsWire
10 days ago
Luke Laffin, MD, Cleveland Clinic, to discuss latest data from the pivotal Advance-HTN and Launch-HTN clinical trials and the potential of lorundrostat in hypertension Luke Laffin, MD, Cleveland Clinic, to discuss latest data from the pivotal Advance-HTN and Launch-HTN clinical trials and the potential of lorundrostat in hypertension
More Mineralys Therapeutics News

Company Profile

Mineralys Therapeutics, Inc. s a clinical-stage biopharmaceutical company engaged in developing medicines to target disease, driven by abnormally elevated aldosterone. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Head office United States
CEO Jon Congleton
Employees 51
Founded 2019
Website www.mineralystx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today